32 completed, 7 unknown, 4 recruiting, 3 active not recruiting. 54 Phase 3, 10 Phase 2.
Follow Atrophy: new trials by email Literature Review of Atrophy trials Research Report on Atrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Prospective, Multi-center Trial Evaluating the Improvement of Nutritional Status and Sarcopenia With Silkworm Pupa Tablets in Patients With Malignancies Silkworm pupa tablets, Placebo - Nutritional Deficiency, Gastrointestinal Cancers | Phase 3 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 480 | 2026-04-01 | 2026-04-28 |
| Regime for Vitamin D Maintenance in Post-Operative Patients Vitamin D - Sarcopenia | Phase 3 | Recruiting | Sengkang General Hospital | 100 | 2026-01-01 | 2026-05-04 |
| The Efficacy of Topical Vaginal Oxytocin Gel in Postmenopausal Women With Vulvovaginal Atrophy Oxytocin, Hydroxypropyl methylcellulose - Vaginal Atrophy, Genitourinary Syndrome of Menopause | Phase 3 | Unknown | Oxagon | 244 | 2024-09-01 | 2024-07-23 |
| Effect of Ketosteril on Sarcopenia in Patients With Chronic Kidney Disease low-protein diet + Ketosteril, low-protein diet - Chronic Kidney Disease, Sarcopenia | Phase 3 | Recruiting | Huashan Hospital | 58 | 2024-05-01 | 2026-07-28 |
| Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes Denosumab Injection, Normal saline injection (1.0ml/ branch) - Sarcopenia, Osteoporosis | Phase 3 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 86 | 2024-02-01 | 2024-08-16 |
| Pediatric Oncology Nutrition Intervention Trial Oral Nutrition Supplement, Tube Feed, Cyproheptadine - Pediatric Cancer, Nutrition Related Cancer | Phase 2 / Phase 3 | Completed | Corey Hawes | 20 | 2024-01-31 | 2026-10-08 |
| Oral Branched-chain Amino Acid Supplementation for Cirrhotic Patients With Sarcopenia Branched-chain amino acid, Placebo - Sarcopenia, Cirrhosis of the Liver | Phase 3 | Enrolling by invitation | Mahidol University | 86 | 2023-11-15 | 2025-09-29 |
| CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease CoQ10, Placebo, HB-HIIT - End Stage Renal Disease | Phase 3 | Recruiting | Vanderbilt University Medical Center | 156 | 2023-06-01 | 2026-01-02 |
| Effect Of Ophiochepalus Striatus Extract On Serum IGF-1 And IL-6 Levels In Elderly Patients With Sarcopenia Ophiochepalus striatus extract, Placebo - Sarcopenia, Geriatric | Phase 2 / Phase 3 | Completed | Universitas Sriwijaya | 80 | 2023-05-01 | 2025-01-31 |
| Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab Apitegromab - Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 | Phase 3 | Active not recruiting | Scholar Rock, Inc. | 238 | 2023-04-17 | 2026-09-01 |
| Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam OAV101 - Spinal Muscular Atrophy | Phase 3 | Completed | Novartis Pharmaceuticals | 27 | 2023-01-12 | 2026-01-13 |
| Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials onasemnogene abeparvovec - Spinal Muscular Atrophy (SMA) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 20 | 2022-12-19 | 2026-07-09 |
| Role of Nutritional Intervention for the Treatment of Sarcopenia in Cirrhotic Patients With Refractory Ascites Candidate to Transjugular Intrahepatic Portosystemic Shunt Placement and Identification of Prognostic Factors Related to Clinical Outcome 12-week nutritional intervention with Friliver dispensing, 12-week nutritional intervention with personalized diet, 12-week nutritional intervention with diet diary to report foods eaten. - Liver Cirrhosis, Refractory Ascites in Patients With Cirrhosis | Phase 3 | Recruiting | The Mediterranean Institute for Transplantation and Advanced Specialized Therapies | 72 | 2022-10-13 | 2026-07-14 |
| A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) MT1621 - Thymidine Kinase 2 Deficiency | Phase 3 | Withdrawn | Zogenix MDS, Inc. | 2022-09-30 | 2023-09-01 | |
| Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam Apitegromab, Placebo - Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 | Phase 3 | Completed | Scholar Rock, Inc. | 188 | 2022-04-14 | 2026-01-22 |
| Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA) OAV101, Sham control - Type 2 Spinal Muscular Atrophy | Phase 3 | Completed | Novartis Pharmaceuticals | 126 | 2022-02-01 | 2026-01-13 |
| Growth Hormone in Decompensated Liver Cirrhosis Growth Hormone - Liver Cirrhosis, Fibrosis | Phase 2 / Phase 3 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 96 | 2022-02-01 | 2025-12-16 |
| Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) OAV101 - Spinal Muscular Atrophy | Phase 3 | Completed | Novartis Pharmaceuticals | 24 | 2021-09-08 | 2024-10-09 |
| The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Randomized Trial OLIMEL 7,6%E / PeriOLIMEL 2,5%E - Nutritional Disorder, Critical Illness | Phase 3 | Withdrawn | RWTH Aachen University | 2020-06-01 | 2022-10-27 | |
| Use of Testosterone to Prevent Post-Surgical Muscle Loss - Pilot Study Aveed 750 MG in 3 ML IM Injection, Normal Saline 3 ML IM Injection - Muscle Atrophy, Surgery | Phase 2 / Phase 3 | Unknown | The Stone Research Foundation for Sports Medicine and Arthritis | 15 | 2020-05-08 | 2021-08-31 |
Showing 20 of 54. Sign in to see all of them.
Sarcopenia (24) · Muscular Atrophy (19) · Muscular Atrophy, Spinal (6) · Motor Activity (5) · Vaginal Diseases (5) · Muscular Diseases (4) · Osteoporosis (4) · Bulbo-Spinal Atrophy, X-Linked (3) · Critical Illness (3) · Frailty (3) · Malnutrition (3) · Spinal Muscular Atrophies of Childhood (3) · Amyotrophic Lateral Sclerosis (2) · Carcinoma, Non-Small-Cell Lung (2)
Pathological Conditions, Anatomical (54) · Pathological Conditions, Signs and Symptoms (54) · Nervous System Diseases (42) · Neurologic Manifestations (42) · Signs and Symptoms (42) · Neuromuscular Manifestations (40) · Muscular Atrophy (23) · Nutritional and Metabolic Diseases (16) · Musculoskeletal Diseases (15) · Pathologic Processes (13) · Metabolic Diseases (9) · Neuromuscular Diseases (9) · Central Nervous System Diseases (8) · Female Urogenital Diseases (8)
Ospemifene (5) · Exercise (3) · Resistance Training (3) · Testosterone (3) · Zolgensma (3) · Health (2) · Proteins (2) · Saline Solution (2) · Sodium Chloride (2) · apitegromab (2) · bimagrumab (2) · mecobalamin (2) · ostarine (2) · Amino Acids, Branched-Chain (1) · Amoxicillin (1)
Novartis Pharmaceuticals (6) · Shionogi (5) · University of Erlangen-Nürnberg Medical School (5) · Eisai Co., Ltd. (2) · GTx (2) · Mahidol University (2) · Scholar Rock, Inc. (2) · University of Saskatchewan (2) · Abbott Nutrition (1) · Cairo University (1) · Centre Hospitalier Universitaire de Nice (1) · Corey Hawes (1) · First Affiliated Hospital of Zhejiang University (1) · Gdansk University of Physical Education and Sport (1) · Huashan Hospital (1)
United States (18) · Italy (9) · Belgium (8) · France (8) · Germany (8) · United Kingdom (8) · Canada (6) · Japan (6) · Netherlands (6) · Australia (5) · China (5) · Spain (5) · Switzerland (5) · Denmark (4) · Poland (4)
Wolfgang Kemmler, PhD (3) · Kazunori Saeki (2) · Klaus Engelke, PhD (2) · Willi A Kalender, PhD (2) · Abel Pereira, investigator (1) · Ahmed Reda, Lecturer (1) · Amr Zahran, Professor (1) · Andreas Wittke, MA (1) · Anja Weissenfels, MA (1) · Assem Anwar (1) · Baback Roshanravan, MD/MPH (1) · Christian Stoppe, MD (1) · Corey J Hawes, DCN, RD, CSO, CNSC, LD (1)
PMID 27138015, PMID 20101013, PMID 20171529, PMID 20980923, PMID 23361170, PMID 25481088, PMID 25923603, PMID 25973477, PMID 25982504, PMID 27780567, PMID 27999607, PMID 28220197, PMID 28840147, PMID 29216285, PMID 29523089, PMID 29562147, PMID 29675640, PMID 30636701, PMID 31397289, PMID 32669140, PMID 32761398, PMID 33345059, PMID 33597289, PMID 34107512, PMID 36070134, PMID 37619252, PMID 38525752, PMID 38877464, PMID 39804575, PMID 40372752, PMID 40818473, PMID 41360993, PMID 41360995, PMID 41475066, PMID 41624165, PMID 42392859
2015 (1), UL1TR001998 (1)